Sharon Townson

Sharon Townson

Company: Monte Rosa Therapeutics

Job title: CTO


Panel Discussion | What’s Next on the Horizon for Targeted Protein Degradation? 5:00 pm

Over the last few years the TPD field has exploded. With more and more degraders heading into the clinic in 2021 than ever before, and with the significant rise of molecular glues, it is important to look at the big picture. During this final panel we will discuss: future directions, opportunities beyond inflammation, neurodegenerative and…Read more

day: Day Two

Molecular Glue Degraders: From Serendipity to Rational Design 11:45 am

Monte Rosa’s QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform enables us to rationally discover molecular glue degraders (MGDs). QuEEN comprises: Degron encyclopedia: A growing catalogue of over 1500 proteins identified through our AI-driven approach, containing proteins of diverse protein classes across therapeutic areas, including highly credentialed targets previously deemed undruggable. Proprietary MGD library: A…Read more

day: Day 1 Track 1 AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.